Bayer will sell its prescription dermatology brands to Denmark’s Leo Pharma, as Bayer will shift its focus to its own drug development pipeline as well as integrating Monsanto.
According to both companies, the portfolio includes prescription skin creams against acne, fungal skin infections and rosacea, as well as some steroidal creams with 2017 revenues exceeding $328 million.
The deal does not include Bayer's over-the-counter brands.
Read the Reuters report